The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: cardiovascular toxicity following therapy with immune checkpoint inhibitor
Cardiovascular toxicities may include:
(1) myocarditis
(2) pericarditis
(3) arrhythmias
(4) heart failure (impaired ventricular function)
(5) vasculitis
Parameters:
(1) cardiac biomarkers
(2) clinical status
(3) new ECG abnormalities
(4) management
|
Biomarkers
|
Clinical Status
|
ECG
|
Management
|
Grade
|
|
abnormal
|
none
|
none
|
supportive
|
G1
|
|
abnormal
|
mild
|
NA
|
NA
|
G2
|
|
abnormal
|
none
|
new without conduction delay
|
NA
|
G2
|
|
abnormal
|
moderate
|
NA
|
NA
|
G3
|
|
abnormal
|
NA
|
new with conduction delay
|
NA
|
G3
|
|
NA
|
decompensation; life threatening
|
NA
|
IV meds or intervention
|
G4
|
